Drug Profile
Research programme: leucine-rich repeat kinase inhibitors - Lundbeck
Alternative Names: LRRK2 inhibitors - LundbeckLatest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Developer Lundbeck A/S; Vernalis; Zenobia Therapeutics
- Class
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for research development in Neurodegenerative-disorders in Europe
- 04 Nov 2017 No recent reports of development identified for research development in Parkinson's-disease in Europe